PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis

Cover Page


Cite item

Full Text

Abstract

Psoriasis is one of the most prevalent chronic inflammatory skin diseases. The severity of its clinical manifestations can vary greatly. Objective assessment of psoriasis severity is required to select an adequate therapy. One of the simplest and most consistent methods used to determine psoriasis severity is to calculate the PASI (Psoriasis Area and Severity Index). This index is based on the doctor’s determination of the sum of indices showing the intensity of the main symptoms of psoriasis: erythema, infiltration and peeling in view of the affected skin area. The PASI can also be used to assess the efficacy of treatment for psoriasis patients.

About the authors

A. A. Kubanov

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. E. Karamova

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Email: karamova@cnikvi.ru
Russian Federation

L. F. Znamenskaya

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Email: noemail@neicon.ru
Russian Federation

V. V. Chikin

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Email: noemail@neicon.ru
Russian Federation

V. V. Kondrashova

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Email: noemail@neicon.ru
Russian Federation

References

  1. Kubanova A.A., Kubanov A.A., Melekhina L.E., Bogdanova E.V. Dermatovenereologic healthcare delivery in Russian Federation. Incidence of sexually transmitted infections and skin disorders, 2013-2015. Vestn Dermatol Venerol 2016; (3): 16-32. [Кубанова А.А., Кубанов А.А., Мелехина Л.Е., Богданова Е.В. Организация оказания медицинской помощи по профилю «дерматовенерология» в Российской Федерации. Динамика заболеваемости инфекциями, передаваемыми половым путем, болезнями кожи и подкожной клетчатки, 2013-2015 гг. Вестн дерматол венерол 2016; (3): 16-32.]
  2. Schmitt J., Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210: 194-199.
  3. Naldi L., Svensson A., Diepgen T. et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003; 120: 738-741.
  4. Puzenat E., Bronsard V., Prey S. et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2); 10-16.
  5. Long C.C., Finlay A.Y., Averill R.W. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol 1992; 128: 1129-1130.
  6. Tiling-Grosse S., Rees J. Assessment of area of involvement in skin disease: a study using schematic figure outlines. Br J Dermatol 1993; 128: 69-74.
  7. Gottlieb A.B., Chaudhari U., Baker D.G. et al. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician’s Global Assessment (PGA): a comparison. J Drugs Dermatol 2003; 2: 260-266.
  8. Fredriksson T, Pettersson U. Severe psoriasisoral therapy with a new retinoid. Dermatologica 1978; 157 (4): 238-244.
  9. Jacobson C.C., Kimball A.B. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004; 151 (2): 381-387.
  10. Augustin M., Krüger K., Radtke M.A. et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology2008; 216 (4): 366-372.
  11. Weiss S.C., Kimball A.B., Liewehr D.J. et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 4: 512-518.
  12. Kirby B., Fortune D.G., Bhushan M. et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000; 142 (4): 728-732.
  13. Marks R., Barton S., Shuttleworth D., Finlay A.Y. Assessment of diseases progress in psoriasis. Arch Dermatol 1989; 125: 235-240.
  14. Carlin C.S., Feldman S.R., Krueger J.G. et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-866.
  15. Khawaja A.R., Bokhari S.M., Tariq R. et al. Disease Severity, Quality of Life, and Psychiatric Morbidity in Patients With Psoriasis With Reference to Sociodemographic, Lifestyle, and Clinical Variables: A Prospective, Cross-Sectional Study From Lahore, Pakistan. Prim Care Companion CNS Disord. 2015; 17 (3): 10.4088.
  16. Mattei P.L., Corey K.C., Kimball A.B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28 (3): 333-337.
  17. Radtke M.A., Augustin M. Economic considerations in psoriasis management Clin Dermatol. 2008; 26: 424-431.
  18. Rudakova A.V., Kubanov A.A. Pharmacoeconomic aspects of treatment of psoriasis with biological drugs. Vestn Dermatol Venerol 2012; (2): 26-31. [Рудакова А.В., Кубанов А.А. Фармакоэкономические аспекты терапии псориаза биологическими препаратами. Вестн дерматол венерол 2012; (2): 26-31.]
  19. Zhang W., Islam N., Ma C., Anis A.H. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015; 33 (4): 327-340.
  20. Nast A., Boehncke W.H., Mrowietz U. et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012; 10 (Suppl 2): S1-95.
  21. Znamenskaya L.F., Frigo N.V., Rotanov S.V. et al. Personalized approach to the selection of therapy for patients with psoriasis. Vestn Dermatol Venerol 2010; (5): 77-83. [Знаменская Л.Ф., Фриго Н.В., Ротанов С.В. и др. Персонализированный подход к выбору терапии больных псориазом с учетом результатов молекулярно-генетических исследований. Вестн дерматол венерол 2010; (5): 77-83.]
  22. Foulkes A.C., Warren R.B. Pharmacogenomics and the resulting impact on psoriasis therapies. Dermatol Clin. 2015; 33 (1): 149-160.
  23. Mrowietz U., Kragballe K., Reich K. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303 (1): 1-10
  24. Feldman S.R., Krueger G.G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl.2): ii65-68.
  25. Grob J.J. Why are quality of life instruments not recognized as reference measures in therapeutic trials of chronic skin disorders? J Invest Dermatol 2007; 127 (10): 2299-2301.
  26. National Clinical Guideline Centre (UK). Psoriasis: assessment and management of psoriasis. 2012.
  27. Ashcroft D.M. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-191.
  28. Harari M., Shani J., Hristakieva E. et al. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead Sea. Int J Dermatol 2000; 39: 913-918.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Kubanov A.A., Karamova A.E., Znamenskaya L.F., Chikin V.V., Kondrashova V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies